Research
Hormonal
GLP-1/Glucagon dual agonists (e.g., mazdutide, survodutide) produce greater weight loss and triglyceride reduction compared to GLP-1 mono-agonists.
Dual agonists targeting GLP-1 and Glucagon receptors (like survodutide) have shown significant weight loss (up to 18.7%) and improved triglyceride levels in Phase 2 trials. These drugs leverage the fat-burning and energy-expenditure effects of glucagon while maintaining glucose control through GLP-1.
GoodSupportsHIGH confidence
Survodutide, a second GLP-1R/GCGR agonist, was more successful and produced up to a − 18.7% reduction in body weight following 46 weeks of treatment in a phase 2 trial in adults with obesity [83]... cotadutide did induce a dose-dependent 4–8 times greater reduction in triglycerides over liraglutide.
Why this rating
Based on Phase 2 trials.
Source
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Robert M. Gutgesell et al. · Diabetes Therapy · 2024
DOI 10.1007/s13300-024-01566-x
narrative_reviewCited 51×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dual incretin agonists (GLP-1R/GIPR) such as tirzepatide offer superior weight loss and glycemic control compared to GLP-1 mono-agonists, with a safety profile comparable to mono-agonists.Strong
- Triple incretin agonists (GLP-1R/GIPR/GCGR) produce superior body weight reduction (up to 24.2%) compared to dual or mono-agonists, approaching the efficacy of bariatric surgery.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →